USPTO serial 79250615
LAMBDA-CAP
Reviewed by CopyMark Law Group
Reg. 5980170Status 708Registered
- Filing date
- Status date
- Registration date
- Feb 11, 2020
- Examiner
- MARTINS, ODETTE
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with LAMBDA-CAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dennis S. Prahl
Dennis S. Prahl Ladas & Parry LLP1040 Avenue of the AmericasNew York, NY 10018-3738United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical, biochemical, biological and biotechnological products intended for industry and science, namely, biological preparations for use in industry and science, diagnostic preparations for clinical and medical laboratory use; chemical, biochemical, biological and biotechnological products, namely, antibodies and antibody particles for development and manufacture of pharmaceutical products; biological products, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, supports and substances for the manufacture of pharmaceutical products ] | SECTION 71 - CANCELLED | — |
| 005 | [ Pharmaceutical and veterinary products, namely, pharmaceutical products for the prevention and treatment of immune system related diseases and disorders, therapeutic vaccines; pharmaceutical preparations, namely, pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases; medicines for human medicine, namely, medicinal preparations for the treatment of infectious diseases and for use in oncology; chemical pharmaceutical products for the diagnosis and treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases; diagnostic preparations for medical use; chemical preparations for pharmaceutical use namely, for diagnosing and treating cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases ] | SECTION 71 - CANCELLED | — |
| 042 | Research and development in the field of pharmaceutical products, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research with respect to pharmaceutical products, biotechnology, therapy, antibody and gene therapy; research, product development and quality control in the field of pharmacy, diagnostics and therapy; research in the field of chemistry and biology; industrial analysis and research services in the field of biochemistry and pharmaceuticals; research and development of antibody products for therapeutic purposes; preparing and conducting chemical, biochemical and biotechnological analysis and research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named LAMBDA-CAP
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 4, 2026 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jun 4, 2026 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jun 1, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 5, 2026 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Feb 11, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 31, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 27, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 20, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 12, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 27, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 27, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 11, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 11, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 26, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 26, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 6, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 21, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 16, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 10, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 10, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 10, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 10, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 20, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 20, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 20, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 21, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 5, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 20, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 20, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 13, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 9, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |